Immunohistochemical analysis of Ki-67 in 140 patients with breast cancer - Correlation with clinicopathological factors and survival

Authors

  • Wilmar José Manoel Mastologista e cirurgião oncológico do Hospital Araújo Jorge (HAJ) e do Centro Brasileiro de Radioterapia, Oncologia e Mastologia (Cebrom), mestre em Genética pela Universidade Católica de Goiás (UCG), doutorando em Ciências da Saúde pela Universidade Federal de Goiás (UFG)
  • Diego Franciel Marques Mühlbeier Acadêmico de Biomedicina da UCG.
  • Leonardo Barcelos de Paula Biólogo, mestrando em Biologia Celular e Molecular pela Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (FMRP-USP).
  • Willana Caparelli Cimino de Araújo Biomédica pela UCG.
  • Fábio Marques de Almeida Biomédico, mestrando em Ciências da Saúde pela UFG.
  • Gustavo Nogueira Caixeta Biomédico, citopatologista, imunoistoquímico do HAJ, mestre em Biologia pela UFG.
  • Élbio Cândido de Paula Médico patologista e professor adjunto do Departamento de Imagenologia e Patologia da UFG, chefe do Setor de Anatomia Patológica do HAJ.
  • Deidimar Cássia Batista Abreu Mastologista e cirurgiã oncológica do HAJ, mestre em Genética pela UCG.
  • Lorena Gonçalves Leal Enfermeira da Seção de Quimioterapia do Cebrom.
  • Vera Aparecida Saddi Biomédica, mestre em Biologia Molecular, doutora em Fisiologia Humana pela USP, coordenadora do Programa de Mestrado em Genética

Keywords:

Breast cancer, Ki-67, Immunodetection, Prognostic factor, Survival

Abstract

The Ki-67 antigen is used to evaluate proliferative activity in several tumors. However the role of the
Ki-67 as a prognostic factor in breast cancer is still undefined. The aim of present study was to analyze
the expression of Ki-67 antigen correlating with clinicopathological factors and survival in patients with
breast cancer. We carried out an immunohistochemical analysis using MIB-1 monoclonal antibody in
140 specimen of breast cancer ofwomen with age between 27 and 90 years. The cut-off point was 25%.The five year overall survival was 77.1%. There was a significant worse survival of patients with node
positive (p < 0.0001), larger tumors (p < 0.0001), more advanced stages (p < 0.0001) and with negative
hormonal receptors (p = 0.019). Patients with Ki-67 immunodetection in more than 25% ofthe tumors
cells showed a poorer outcome when compared with those that express Ki-67 in less than 25% of the
cells examined (70.8% x 82.7%), however this difference was not statistically significative (p = 0,094).
The overexpression of Ki-67 did not correlate with a worse survival in the group ofpatients analyzed.

Downloads

Download data is not yet available.

References

1. Laguens G, Coronato S, Girolamo W. Biomarkers in breast cancer.

Cent Eur J Med. 2006;1(4):330-47.

2. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D,

Piccart MJ. Proliferative markers as prognostic and predictive

tools in early breast cancer: where are we now? Ann Oncol. 2005;

16:1723-39.

3.

4.

Schindlbeck C, Kampik T, Janni W, Rack B, Jeschke U, Krajewski

S, et al. Prognostic relevance of disseminated tumor cells in the

bone marrow and biological factors of 265 primary breast carcinomas. Breast Cancer Res. 2005;7:1174-85.

Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach

C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol. 1991;138:867-73.

5. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse

monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31:13-20.

6.

7.

8.

9.

Gerdes J, Lemke H, Baisch H, Wacker H-H, Schwab U, Stein Н.

Cell cycle analysis of a cell proliferation-associated human nuclear

antigen defined by the monoclonal antibody Ki-67. J Immunol.

1984;133:1710-5.

Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch

A, et al. Ki-67 expression in breast carcinoma: its association with

grading systems, clinical parameters, and other prognostic factors

- a surrogate marker? Cancer. 2003;97:1321-31.

Spyratos F, Ferrero-Poüs M, Trassard M, Hacène K, Phillips E,

Tubiana-Hulin M, et al. Correlation between MIB-1 and other

proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer. 2002;94(8):2151-9.

Fonatsch C, Duchrow M, Rieder H, Schlüter C, Gerdes J. Assignment of the human Ki-67 gene (MK167) to 10q25-qter. Genomics. 1991;11:476-7.

10. Schlüter C, Duchrow M, Wohlenberg C, Becker MHG, Key G,

Flad H-D, et al. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol. 1993;123:513-22.

11. Kill IR. Localisation of the Ki-67 antigen within the nucleolus:

evidence for a fibrillarin-deficient region of the dense fibrillar component. J Cell Sci. 1996;109:1253-63.

12. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki67 in early breast cancer. J Clin Oncol. 2005;23:7212-20.13.

14.

15.

Shaaban AM, Sloane JP, West CR, Foster CS. Breast cancer risk

in usual ductal hyperplasia is defined by estrogen receptor-α and

Ki-67 expression. Am J Pathol. 2002;160:597-604.

Mirza AN, Mirza NQ, Vlastos G, Singletary SE. Prognostic factors in node-negative breast cancer: a review of studies with sample

size more than 200 and follow-up more than 5 years. Ann Surg.

2002;235:10-26.

Azambuja E, Cardoso F, De Castro Jr G, Colozza M, Mano MS,

Durbecq V, et al. Ki-67 as a prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients.

Br J Cancer. 2007;96:1504-13.

16. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation

markers and survival in early breast cancer: A systematic review

and meta-analysis of 85 studies in 32,825 patients. Breast. 2008;

17(4):323-34.

17. Mendonça GAS, Silva AM, Caula WM. Características tumorais e

sobrevida de cinco anos em pacientes com câncer de mama admitidas no Instituto Nacional de Câncer, Rio de Janeiro, Brasil. Cad

Saúde Pública. 2004;20(5):1232-9.

18. Park D, Kåresen R, Noren T, Sauer T. Ki-67 expression in primary

breast carcinomas and their axillary lymph node metastases: clinical implications. Virchows Arch. 2007;451:11-8.

Downloads

Published

2026-07-27

How to Cite

Manoel, W. J., Mühlbeier, D. F. M., de Paula, L. B., de Araújo, W. C. C., de Almeida, F. M., Caixeta, G. N., … Saddi, V. A. (2026). Immunohistochemical analysis of Ki-67 in 140 patients with breast cancer - Correlation with clinicopathological factors and survival. Mastology, 19(3). Retrieved from https://mastology.org/journal/article/view/2041

Issue

Vol. 19 No. 3 (2009)

Section

Original Articles

License

Copyright (c) 2026 Wilmar José Manoel, Diego Franciel Marques Mühlbeier, Leonardo Barcelos de Paula, Willana Caparelli Cimino de Araújo, Fábio Marques de Almeida, Gustavo Nogueira Caixeta, Élbio Cândido de Paula, Deidimar Cássia Batista Abreu, Lorena Gonçalves Leal, Vera Aparecida Saddi

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.